Becton Dickinson reported this week that its BD Diagnostics business logged a 6 percent increase in fiscal fourth quarter revenues and a 5 percent increase in fiscal 2013 full-year revenues, with Q4 driven in part by sales of the company's BD Max molecular testing system.

In addition, executives from the company disclosed that the commercialization timelines for several of its molecular diagnostic tests currently under development, as well as its forthcoming next-generation Viper molecular testing platform, have been delayed by at least a quarter.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Browse our free articles
You can still register for access to our free content.